MPL and essential thrombocythemia: Myeloproliferative neoplasms patients are characterized by a JAK2V617F point mutation in 95% of PV and 60% of ET and PMF 3–4; furthermore, 5 or 10% of ET and PMF patients harbour mutations in MPL, respectively 5–8.